Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-Resistant viral strains
摘要:
Indinavir analogues with blocked metabolism sites show highly improved pharmacokinetic profiles in animals. The cis aminochromanol substituted analogues exhibited excellent potency against both the wild-type (NL4-3) virus and protease inhibitor-resistant HIV strains. (C) 2002 Elsevier Science Ltd. All rights reserved.
Spiroxatrine derivatives towards 5-HT1A receptor selectivity
作者:Claudia Sorbi、Annalisa Tait、Umberto M. Battisti、Livio Brasili
DOI:10.1007/s43440-019-00039-4
日期:2020.4
values in a μM-nM range at the 5-HT1Areceptor, while they are practically inactive at 5-HT1B and 5-HT1D subtypes. Compound 11, the best of the series, has a 5-HT1A pKi value of 8.43 similar to spiroxatrine but, notably, it has a 5-HT1A favorable selectivity ratio of 52, 8 and 29, respectively over α2A, α2B and α2C adrenoceptor subtypes. CONCLUSIONS In this SAR study, a 5-HT1A selective ligand has been
背景技术在我们以前的工作中,螺索沙汀被用作开发选择性NOP配体的参考化合物。因此,合成了几种三氮杂螺并十二烷酮衍生物。在这里,我们验证了它们对其他5-HT1受体亚型以及对α2-AR(肾上腺素能受体)的选择性。方法在表达人类克隆的5-HT1A / B / D和α2A/ B / C亚型受体的细胞上测定结合亲和力。测定具有至少50%放射性配体抑制的那些的Ki值。结果我们所有的衍生物对α2亚型均显示中等亲和力,范围从5到7.5 pKi。此外,它们在5-HT1A受体上的亲和力值在μM-nM范围内,而在5-HT1B和5-HT1D亚型上却几乎没有活性。该系列中最好的化合物11的5-HT1A pKi值为8.43,与spiroxatrine类似,但是,值得注意的是,与α2A,α2B和α2C肾上腺素受体亚型相比,它具有5-HT1A有利的选择性比,分别为52、8和29。结论在这项SAR研究中,已鉴定出5-HT1
3-Piperidino-1-chromanol derivatives and analogs having the formula
wherein
A and B are taken together and are -CH₂CH₂- or A and B are taken separately and are each H;
X is CH₂ or O,
X¹ is H or OH;
Z is H, F, Cl, Br or OH;
Z¹ is H, F, Cl, Br or (C₁-C₃)alkyl;
n is 0 or 1; and
m is 0 or an integer from 1 to 6;
pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds.
式中的 3-哌啶基-1-色醇衍生物及类似物
其中
A 和 B 合起来是-CH₂CH₂-,或 A 和 B 分开来各自是 H;
X 是 CH₂ 或 O、
X¹ 是 H 或 OH;
Z 是 H、F、Cl、Br 或 OH;
Z¹ 是 H、F、Cl、Br 或 (C₁-C₃)烷基;
n 是 0 或 1;以及
m 是 0 或 1 至 6 的整数;
其药物组合物;用其治疗中枢神经系统疾病的方法;以及用于制备上述化合物的中间体。
[EN] NEUROPROTECTIVE 3-PIPERIDINO-4-HYDROXYCHROMAN DERIVATIVES AND ANALOGS
申请人:PFIZER INC.
公开号:WO1991012005A1
公开(公告)日:1991-08-22
(EN) 3-Piperidino-1-chromanol derivatives and analogs having formula (I), wherein A and B are taken together and are -CH2CH2- or A and B are taken separately and are each H; X is CH2 or O; X1 is H or OH; Z is H, F, Cl, Br or OH; Z1 is H, F, Cl, Br or (C1-C3)alkyl; n is 0 or 1; and m is 0 or an integer from 1 to 6; pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds.(FR) Les dérivés et analogues de 3-Piperidino-1-chromanol ayant la formule (I), dans laquelle A et B sont pris ensemble et représentent -CH2CH2- ou A et B sont pris séparément et représentent chacun H; X représente CH2 ou O; X1 représente H ou OH; Z représente H, F, Cl, Br ou OH; Z1 représente H, F, Cl, Br ou alkyle contenant 1 à 3 atomes de carbone; n représente 0 ou 1; et m représente 0 ou un nombre entier compris entre 1 et 6; leurs compositions pharmaceutiques, procédés de traitement de trouble du système nerveux central à l'aide desdites compositions; et intermédiaires utiles dans la préparation desdits composés.
3- Piperidino-1-chroman-3-ol 的衍生物及其同分异构体、具有式 (I) 的结构式 I,其中 A 和 B 考虑在一起时可连接成 - - 或单独为 H; X 为 CH2 或 O; X1 为 H 或 OH; Z 为 H、F、Cl、Br 或 OH; Z1 为 H、F、Cl、Br 或含 1-3 个碳原子的烷基; n 为 0 或 1; m 为 0 或 1-6 的整数; 该类化合物的给药制剂; 治疗中枢神经系统病症时使用的治疗方法; 以及用于合成上述化合物的中间体。
Colonge; Guyot, Bulletin de la Societe Chimique de France, 1958, p. 325,328
作者:Colonge、Guyot
DOI:——
日期:——
A NEW SYNTHESIS OF <i>CIS-</i>3-SUBSTITUTED CHROMAN-4-OLS
作者:M. Venkati、G. L. David Krupadanam
DOI:10.1081/scc-120005433
日期:2002.1.1
3,3-Dibromochroman-4-ones on reaction with different heterocyclic secondary amines gave 3-substituted chromones. These on reduction with NaBH4 gave exclusively cis-3-heterocycle substituted chroman-4-ols in good yields.